<DOC>
	<DOCNO>NCT01694849</DOCNO>
	<brief_summary>Abdominal obesity type-2 Diabetes associate chronic liver disorder result accumulation fat liver ( steatosis ) , may progress towards hepatitis possibly lead cirrhosis liver cancer . NAFLD ( Non Alcoholic Fatty Liver Disease ) consider common form chronic liver disease adult United States , Australia , Asia Europe . In USA , estimate prevalence NAFLD 20-30 % adult population . Non-alcoholic Steatohepatitis ( NASH ) progress form NAFLD , correspond hepatic steatosis associate inflammation liver cell injury upon microscopic examination liver biopsy . This condition may lead advanced fibrosis cirrhosis deserve serious medical management . Up , effective drug clearly demonstrate therapeutic efficacy may help lifestyle dietary recommendation resolution NASH . In context , GENFIT develop new liver target drug candidate , GFT505 , treatment NASH reduction multiple cardiometabolic risk factor associate metabolic syndrome type 2 Diabetes . This phase IIb study evaluate efficacy safety GFT505 80mg 120mg daily 52 week reversal NASH without worsen fibrosis , base liver biopsy assessment .</brief_summary>
	<brief_title>Phase IIb Study Evaluate Efficacy Safety GFT505 Versus Placebo Patients With Non-Alcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description>The study duration per patient 80 week . A screening period ( 4 16 week ) precede 52-week double-blind treatment period 3 month follow-up period . The study conduct 270 patient ( 90 patient placebo arm , 90 patient GFT505 80mg arm , 90 patient GFT505 120mg arm ) . Enrollment perform two phase : first phase , patient receive either GFT505 dose 80 mg either placebo . An independent expert committee review safety data 45 patient receive dose 80 mg treat 6 month . The committee approval necessary start second phase , patient receive either GFT505 dose 80 mg , GFT505 dose 120 mg placebo .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Males female ( female must either nonchild bear potential use efficient double contraception ) . For male participant , contraceptive measure must take study , either male participant female partner . Body Mass Index ≤ 45 kg/m² . Patients agree one liver biopsy screen period diagnostic purpose ( historical biopsy within 6 month randomization available ) one end treatment period assessment treatment effect . For hypertensive patient , hypertension must control stable dose antihypertensive medication least 2 month prior screen ( stable dose maintain throughout study ) . Patients treat vitamin E ( &gt; 400IU/d ) , Polyunsaturated fatty acid ( &gt; 2g/day ) Ursodeoxycholic acid include drug stop least 3 month prior diagnostic liver biopsy end study . Histological confirmation steatohepatitis diagnostic liver biopsy . Histological diagnostic confirm central reading slide ( steatosis &gt; 5 % + lobular inflammation , grade + ballooning , amount ) . For patient Type 2 Diabetes , glycemia must control ( Glycosylated Haemoglobin A1c ≤8.5 % ) . If glycemia control antidiabetic drug , qualitative change permit within 6 month prior randomization avoid study . Treatments metformin , Dipeptidyl Peptidase 4 inhibitor , Glucagonlike peptide1 agonist , sulfamides , insulin authorize . Sulfamides insulin permit glycemia selfmonitored patient . Known heart failure ( Grade I IV New York Heart Association classification ) . Weight loss 5 % within 6 month prior randomization . History bariatric surgery . Uncontrolled Blood Pressure . Type 1 diabetes patient . Patients acute cardiovascular episode within 6 month prior screen , history coronary angioplasty , history stroke , Transient Ischemic Attack , Coronary Heart Disease . Compensated uncompensated cirrhosis . Notably , NASH patient fibrosis stage = 4 accord NASH CRN fibrosis stag system exclude . Known alcohol and/or drug abuse dependence last five year . Pregnant lactating female . Other well documented cause chronic liver disease Known intolerance contraindication list excipients GFT505 . Evidence unstable , untreated clinically significant immunological , neoplastic , endocrine , haematological , gastrointestinal , neurological psychiatric disorder . Positive HBsAg ( Hepatitis B Surface Antigen ) , Positive antiHIV , positive HCVRNA ( Hepatitis C Virus ) . Uncontrolled hypothyroidism define Thyroid Stimulating Hormone &gt; 2X upper limit normal ( ULN ) . Thyroid dysfunction control least 6 month prior screen permit . Significant renal disease , include nephritic syndrome , chronic renal failure ( defined creatinine clearance &lt; 60 mL/mn serum creatinine &gt; 180 μmol/L ) . Unexplained serum creatine phosphokinase ( CPK ) &gt; 3X upper limit normal ( ULN ) . Patients reason CPK elevation may measurement repeat prior randomization ; CPK retest &gt; 3X ULN lead exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>PPARs</keyword>
	<keyword>NASH</keyword>
	<keyword>Non-Alcoholic Steatohepatitis</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Fibrosis</keyword>
</DOC>